3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

Characterization of TP53 mutations in actionable driver-negative non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

A woman receiving an IV at the hospital. This article is part of an ongoing series on novel cancer advances, including immunotherapies such as CAR T therapy and checkpoint inhibitors. Future ...

Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, ...

Please provide your email address to receive an email when new articles are posted on . Adding immune checkpoint inhibitors to neoadjuvant chemotherapy benefited certain patients with early-stage ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Epithelioma Treatment Market to reach USD 13.1 billion by 2035, driven by rising skin cancer cases and growing adoption of ...